Speaking at the 2019 ATS conference in Dallas, TX, USA, Babak Mokhlesi (University of Chicago, Chicago, IL, USA) discusses the link between obstructive sleep apnoea, insufficient sleep duration and type 2 diabetes; key findings of his study, and the implications for the prevention and treatment of type 2 diabetes.
1. What is the link between obstructive sleep apnoea, insufficient sleep duration and type 2 diabetes? (0:04)
2. What unmet needs are there currently in patients with type 2 diabetes/pre-diabetes with respect to obstructive sleep apnoea? (2:44)
Speaker disclosure: Babak Mokhlesi has nothing to disclose in relation to this video interview.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at ATS 2019, Dallas, TX, USA, May 2019.
Share this Video
Related Videos In Sleep Related Breathing Disorders
Carolyn D’Ambrosio, CHEST 2020 – Sleep Apnea in Women
We caught up with Dr Caroyln D’Ambrosio (Brigham and Women’s Hospital, Boston, MA, USA) to discuss obstructive sleep apnea in women. Questions What proportion of sleep apnea patients are female? (0:23) What are the risk factors for sleep apnea in women? (1:02) How do sleep apnea symptoms in women differ from those in men? (1:36) […]
Jan Hedner, ERS 2019 – Carbon Anhydrase Inhibitors for Treatment of Obstructive Sleep Apnoea
We met Jan Hedner, of Gothenburg, Sweden, at ERS 2019, who talks us through the latest evidence for the effectiveness of carbon anhydrase inhibitors for treatment of obstructive sleep apnoea. Questions 1. What are the limitations of continuous positive airway pressure (CPAP) in the treatment of obstructive sleep apnoea (OSA)? (0:05) 2. What properties of […]
Luigi Montemurro, ERS 2019 – Ato-oxy for Obstructive Sleep Apnoea
Luigi Montemurro, of Brigham and Women’s Hospital in Boston, met us at ERS 2019 in Madrid to discuss the recent trial of the fixed dose combination of atomoxetine and oxybutynin as the first successful pharmacotherapy for obstructive sleep apnoea. Questions 1. Why is there not yet an effective pharmacotherapy for obstructive sleep apnoea (OSA)? (0:05) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!